Neurotech International Limited
On 12 September 2016 (“Prospectus Date”), Neurotech International Limited (ACN 610 205 402) (“Neurotech” or “the Company”) lodged a prospectus (“Prospectus”) with the Australian Securities and Investments Commission (“ASIC”) for the offer of 35,000,000 fully paid ordinary shares in the Company (“Shares”) at an issue price of 20 cents per Share to raise $7,000,000, and the offer of up to 2,529,076 options to acquire Shares to the Lead Manager (as those terms are defined in the Prospectus).
THE OFFER HAS NOW CLOSED, AND THE COMPANY IS NO LONGER ACCEPTING APPLICATIONS FOR SHARES.
An electronic copy of the Prospectus can be obtained in PDF format by clicking below after confirming agreement to the following.
This is an important document that should be read in its entirety. If you do not understand it, you should consult your professional adviser without delay. The paper form of the electronic Prospectus is accessible through this website has been lodged with ASIC.
Applications for securities referred to in the Prospectus must be made in accordance with the terms and conditions set out in the Prospectus. Applications for securities must be made on an application form that accompanies a complete hard copy of the Prospectus. There is no facility for online applications.
The Company will not issue any Shares on the basis of this Prospectus later than 13 months after the Prospectus Date.
The Prospectus does not constitute an offer in any place in which, or to any person to whom, it will not be lawful to make such an offer. No action has been taken to lodge, register or file the Prospectus in any jurisdiction outside Australia. The distribution of this Prospectus outside Australia may be restricted by law and persons who come into possession of this Prospectus outside Australia should seek advice on and observe any such restrictions. The investment described in this Prospectus has not been recommended by any regulatory authority of any jurisdiction including ASIC.
The information on this website is provided for information purposes only and is subject to change without notice. Nothing contained on this website or in the Prospectus constitutes investment, legal, accounting, business, tax or other advice. The information on this website and in the Prospectus does not take into account your investment objectives, financial situation or particular needs. The information on this website does not form part of the Prospectus.
By accessing the Prospectus, you are taken to have confirmed that you have read and understood the notice and agree to these terms and conditions.
Neurotech’s Scientific Advisory Board acts as strategic counsel to Neurotech, guiding company management as it enters the market with its Mente Autism device, in addition to the development of other devices targeting various neurological disorders.
Dr David S. Cantor
Dr David Cantor received his Bachelor’s Degree with Distinction in Psychology from the University of Connecticut. His honours work was in the field of neurophysiological correlates of cross modal integration processes in attention deficit disorders. He received his Masters and Doctorate in psychology at the State University of New York (Stony Brook), where his thesis was focussed on quantitative EEG correlates of autism. He most recently received his Postdoctoral Masters of Science in Psychopharmacology from Fairleigh University.
Dr Cantor is a Fellow with the American College of Forensic Examiners, National Academy of Neuropsychology, and the Academy of Learning and Developmental Disorders. He is also Former President of the EEG and Clinical Neuroscience Society and has also been accepted for special fellowships including Congressional Fellow of the American Psychological Association and the State of New York Intercampus Fellow in the area of brain research. He has been awarded the Joel Lubar Award for his contributions in the field of Neurofeedback and most recently was elected as President-Elect of the International Society of Neurofeedback and Research (ISNR). More recently, Dr Cantor has been named as president-elect of the International Society for Neurofeedback and Research (ISNR). The announcement was made at this year’s international conference in Glendale, Arizona, which the Company also attended, with Dr Cantor taking up office in 2020.
The ISNR is a membership organization comprised of experts from many countries and professional disciplines doing neurotherapy, neurofeedback training and research. ISNR supports education and excellence in the field of neurofeedback training and neurotherapy and seeks the validation and acceptance of this discipline by a broad spectrum of society.
Dr Emanuela Russo
Dr Emanuela Russo joined Neurotech in 2016 as Head of Scientific and Clinical Research. Prior to that, she was Adjunct Professor “Niccolò Cusano” University of Rome. She graduated in Clinical Psychology and has a doctorate in Cognitive Psychology and Psychophysiology from the “Sapienza” University of Rome.
Her research interests regard the brain correlates of attention and perception as well as the neural patterns underpinning cognitive-emotional states. She is specialized in the brain activity and its utilization as a clinical investigational tool for the evaluation of brain dysfunction. She is focused in the identification of biomarkers within broad categories of disorders (anxiety disorders, depression, ADHD, ASD) and how these indices can be remarkable in the prediction of treatment outcomes and in the development of neuromodulation interventions. In 2012, she received the ‘Best Young Researcher’ award at the IOP Congress in Pisa (Italy). She has held various positions as lecturer and Adjunct Professor since 2008. She has also been a reviewer for several scientific journals.
Dr Tanju Surmeli
Dr Tanju Surmeli received his Medical Doctor degree from Dokuz Eylül University in Izmir, Turkey. He completed two years obligatory service for the Turkish Government and army service as a lieutenant. Dr Surmeli attended Harvard Medical School’s Global Clinical Scholars Research Training Program and completed a Research Fellowship in EEG and psychopharmacology at New York Medical College. He did his post-doctoral training in Family therapy at the Ackerman Institute for Family Therapy, worked at the Manic depression Foundation and Colombia-NYSPI under Prof Ronald Fieve and learned hypnosis at the Milton Ericson Hypnosis Institute.
Dr Surmeli did his residency training in Psychiatry and Neurology at University of Connecticut/Institute of Living, Yale, and University of Texas, San Antonio. He is a board and ECFM certified psychiatrist. His associate professorship application is under reviewal by the Turkish Higher Education Board's appointed jury for works reviewal. In 2001, he founded the Healthy Living Polyclinic and is also the founder of the Biofeedback, Neurofeedback and QEEG/ERP use in Psychiatry Foundation. He is the only BCIAC-EEG certified psychiatrist in Turkey.
Dr Evian Gordon
Dr Evian Gordon is the Executive Chairman of Brain Resource. He established an “Integrative Neuroscience” approach, grounded in the use of standardized methods across multiple types of brain data in a single platform, with over a million datasets. He founded the Brain Resource Company that created the first standardized international database on the human brain (over 300 publications). The database is the asset which shapes the development of MyBrainSolutions.com and TotalBrain.com for brain health and peak performance, used in Wellness Programs in more than 30 Fortune 500 Companies and more than 600,000 employees (including Boeing, AARP, Cerner). The first genetics test using this methodology (in 1700 patients) for treatment prediction in depression, is currently being completed for potential use in clinical practice.
Based in San Francisco, Dr Gordon has published more than 300 scientific papers and two books (Integrative Neuroscience and The Brain Revolution).